Combination therapy of cefmenoxime and aminoglycosides for infections in the patients with hematological diseases

Keisuke Toyama, Isao Aoki, Hajime Nakazawa, Kiyoko Miyake, Kunihiko Sato, Shinichiro Okamoto, Takuro Shimbo, Yasuoi Keda, Yasuhiko Ando, Hiroshiu Chida, Junsei Wada, Makoto Asano, Yuzo Shinozaki, Mitsuo Kitahara, Yukinori Takahashi, Yasuo Ikeda, Masao Kikuchi, Fuyuhiko Higashi, Ichiro Takeuchi, Gota Masuda

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Combination therapy of cefmenoxime (CMX) and aminoglycosides (TOB, AMK, GM) was evaluated in 52 cases with infections accompanied by hematological diseases (leukemia, aplastic anemia etc.). Clinical responses among 41 evaluable cases out of 52 were excellent in 8, good in 13, fair in 10, and overall effective rate was 51.2%. The efficacy of this therapy decreased proportionally with the reduction of the number of peripheral mature granulocyte count, but 12 out of 29 cases with granulocyte counts less than 500/μl including 10 cases with 0/μ;l still responded (41.3%). The effective rate was 30% even in the definite immunocompromized hosts, namely in the terminal stages in hematological diseases. Serum concentrations of CMX and aminoglycosides were far above minimum inhibitory concentrations of isolated organisms. No significant side effects were observed in this combination therapy except for eruption in a case and slight renal dysfunction in 2 cases. These results indicate that the combination therapy of CMX and aminoglycosides are useful for the treatment of severe infections complicated with hematological diseases.

Original languageEnglish
Pages (from-to)704-711
Number of pages8
JournalChemotherapy
Volume33
Issue number8
DOIs
Publication statusPublished - 1985

Fingerprint

Cefmenoxime
Hematologic Diseases
Aminoglycosides
Infection
Granulocytes
Therapeutics
Amikacin
Aplastic Anemia
Microbial Sensitivity Tests
Leukemia
Kidney
Serum

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Combination therapy of cefmenoxime and aminoglycosides for infections in the patients with hematological diseases. / Toyama, Keisuke; Aoki, Isao; Nakazawa, Hajime; Miyake, Kiyoko; Sato, Kunihiko; Okamoto, Shinichiro; Shimbo, Takuro; Keda, Yasuoi; Ando, Yasuhiko; Chida, Hiroshiu; Wada, Junsei; Asano, Makoto; Shinozaki, Yuzo; Kitahara, Mitsuo; Takahashi, Yukinori; Ikeda, Yasuo; Kikuchi, Masao; Higashi, Fuyuhiko; Takeuchi, Ichiro; Masuda, Gota.

In: Chemotherapy, Vol. 33, No. 8, 1985, p. 704-711.

Research output: Contribution to journalArticle

Toyama, K, Aoki, I, Nakazawa, H, Miyake, K, Sato, K, Okamoto, S, Shimbo, T, Keda, Y, Ando, Y, Chida, H, Wada, J, Asano, M, Shinozaki, Y, Kitahara, M, Takahashi, Y, Ikeda, Y, Kikuchi, M, Higashi, F, Takeuchi, I & Masuda, G 1985, 'Combination therapy of cefmenoxime and aminoglycosides for infections in the patients with hematological diseases', Chemotherapy, vol. 33, no. 8, pp. 704-711. https://doi.org/10.11250/chemotherapy1953.33.704
Toyama, Keisuke ; Aoki, Isao ; Nakazawa, Hajime ; Miyake, Kiyoko ; Sato, Kunihiko ; Okamoto, Shinichiro ; Shimbo, Takuro ; Keda, Yasuoi ; Ando, Yasuhiko ; Chida, Hiroshiu ; Wada, Junsei ; Asano, Makoto ; Shinozaki, Yuzo ; Kitahara, Mitsuo ; Takahashi, Yukinori ; Ikeda, Yasuo ; Kikuchi, Masao ; Higashi, Fuyuhiko ; Takeuchi, Ichiro ; Masuda, Gota. / Combination therapy of cefmenoxime and aminoglycosides for infections in the patients with hematological diseases. In: Chemotherapy. 1985 ; Vol. 33, No. 8. pp. 704-711.
@article{32c9009b28b740c6bbdff0696cf6fed3,
title = "Combination therapy of cefmenoxime and aminoglycosides for infections in the patients with hematological diseases",
abstract = "Combination therapy of cefmenoxime (CMX) and aminoglycosides (TOB, AMK, GM) was evaluated in 52 cases with infections accompanied by hematological diseases (leukemia, aplastic anemia etc.). Clinical responses among 41 evaluable cases out of 52 were excellent in 8, good in 13, fair in 10, and overall effective rate was 51.2{\%}. The efficacy of this therapy decreased proportionally with the reduction of the number of peripheral mature granulocyte count, but 12 out of 29 cases with granulocyte counts less than 500/μl including 10 cases with 0/μ;l still responded (41.3{\%}). The effective rate was 30{\%} even in the definite immunocompromized hosts, namely in the terminal stages in hematological diseases. Serum concentrations of CMX and aminoglycosides were far above minimum inhibitory concentrations of isolated organisms. No significant side effects were observed in this combination therapy except for eruption in a case and slight renal dysfunction in 2 cases. These results indicate that the combination therapy of CMX and aminoglycosides are useful for the treatment of severe infections complicated with hematological diseases.",
author = "Keisuke Toyama and Isao Aoki and Hajime Nakazawa and Kiyoko Miyake and Kunihiko Sato and Shinichiro Okamoto and Takuro Shimbo and Yasuoi Keda and Yasuhiko Ando and Hiroshiu Chida and Junsei Wada and Makoto Asano and Yuzo Shinozaki and Mitsuo Kitahara and Yukinori Takahashi and Yasuo Ikeda and Masao Kikuchi and Fuyuhiko Higashi and Ichiro Takeuchi and Gota Masuda",
year = "1985",
doi = "10.11250/chemotherapy1953.33.704",
language = "English",
volume = "33",
pages = "704--711",
journal = "Chemotherapy",
issn = "0009-3165",
publisher = "S. Karger AG",
number = "8",

}

TY - JOUR

T1 - Combination therapy of cefmenoxime and aminoglycosides for infections in the patients with hematological diseases

AU - Toyama, Keisuke

AU - Aoki, Isao

AU - Nakazawa, Hajime

AU - Miyake, Kiyoko

AU - Sato, Kunihiko

AU - Okamoto, Shinichiro

AU - Shimbo, Takuro

AU - Keda, Yasuoi

AU - Ando, Yasuhiko

AU - Chida, Hiroshiu

AU - Wada, Junsei

AU - Asano, Makoto

AU - Shinozaki, Yuzo

AU - Kitahara, Mitsuo

AU - Takahashi, Yukinori

AU - Ikeda, Yasuo

AU - Kikuchi, Masao

AU - Higashi, Fuyuhiko

AU - Takeuchi, Ichiro

AU - Masuda, Gota

PY - 1985

Y1 - 1985

N2 - Combination therapy of cefmenoxime (CMX) and aminoglycosides (TOB, AMK, GM) was evaluated in 52 cases with infections accompanied by hematological diseases (leukemia, aplastic anemia etc.). Clinical responses among 41 evaluable cases out of 52 were excellent in 8, good in 13, fair in 10, and overall effective rate was 51.2%. The efficacy of this therapy decreased proportionally with the reduction of the number of peripheral mature granulocyte count, but 12 out of 29 cases with granulocyte counts less than 500/μl including 10 cases with 0/μ;l still responded (41.3%). The effective rate was 30% even in the definite immunocompromized hosts, namely in the terminal stages in hematological diseases. Serum concentrations of CMX and aminoglycosides were far above minimum inhibitory concentrations of isolated organisms. No significant side effects were observed in this combination therapy except for eruption in a case and slight renal dysfunction in 2 cases. These results indicate that the combination therapy of CMX and aminoglycosides are useful for the treatment of severe infections complicated with hematological diseases.

AB - Combination therapy of cefmenoxime (CMX) and aminoglycosides (TOB, AMK, GM) was evaluated in 52 cases with infections accompanied by hematological diseases (leukemia, aplastic anemia etc.). Clinical responses among 41 evaluable cases out of 52 were excellent in 8, good in 13, fair in 10, and overall effective rate was 51.2%. The efficacy of this therapy decreased proportionally with the reduction of the number of peripheral mature granulocyte count, but 12 out of 29 cases with granulocyte counts less than 500/μl including 10 cases with 0/μ;l still responded (41.3%). The effective rate was 30% even in the definite immunocompromized hosts, namely in the terminal stages in hematological diseases. Serum concentrations of CMX and aminoglycosides were far above minimum inhibitory concentrations of isolated organisms. No significant side effects were observed in this combination therapy except for eruption in a case and slight renal dysfunction in 2 cases. These results indicate that the combination therapy of CMX and aminoglycosides are useful for the treatment of severe infections complicated with hematological diseases.

UR - http://www.scopus.com/inward/record.url?scp=0022404461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022404461&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.33.704

DO - 10.11250/chemotherapy1953.33.704

M3 - Article

VL - 33

SP - 704

EP - 711

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3165

IS - 8

ER -